Decoy Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Decoy Therapeutics Inc. (DCOY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -2.80% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2019-03-06
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was -2.80%.
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was -1.90%.
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was -2.60%.
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2015 was -6.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 10 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 10 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 22 month |
|---|---|---|---|---|
| 2018-12-31 | -2.80% 10-K · filed 2019-03-06 | |||
| 2017-12-31 | -1.90% 10-K · filed 2019-03-06 | |||
| 2016-12-31 | -2.60% 10-K · filed 2019-03-06 | |||
| 2015-12-31 | -6.30% 10-K · filed 2018-03-07 | -5.30% 10-K · filed 2016-03-08 | ||
| 2014-12-31 | -34.30% 10-K · filed 2017-03-08 | -5.30% 10-K · filed 2015-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |